FDA’s Drug Safety Office Reorganizing To Accommodate Influx Of PDUFA Staff
This article was originally published in The Tan Sheet
Executive Summary
FDA's Office of Surveillance and Epidemiology continues changing to strengthen its drug safety operations by reorganizing prior to increasing staff by 50 percent to undertake new regulatory authorities
You may also be interested in...
FDA’s 5-Year Plan For User Fees Gives Equal Footing To Post- And Pre-Market
Over the next five years, FDA will shift its regulatory focus to ensure that the safe and effective use of drugs is of equal importance as ushering safe and effective medicines to market
FDA’s 5-Year Plan For User Fees Gives Equal Footing To Post- And Pre-Market
Over the next five years, FDA will shift its regulatory focus to ensure that the safe and effective use of drugs is of equal importance as ushering safe and effective medicines to market
FDA’s 5-Year Plan For User Fees Gives Equal Footing To Post- And Pre-Market
Over the next five years, FDA will shift its regulatory focus to ensure that the safe and effective use of drugs is of equal importance as ushering safe and effective medicines to market